S.Res. 648Senate115th Congress (2017-2019)Passed Congress

A resolution designating September 2018 as "Pulmonary Fibrosis Awareness Month".

Introduced September 25, 2018

AI-Generated Summary

Updated April 15, 2026 at 11:46 PM UTC

The Senate resolution designates September 2018 as Pulmonary Fibrosis Awareness Month. It aims to raise public awareness about this serious lung disease, highlight the need for research, and recognize the efforts of patients, caregivers, and organizations working on the condition.

Key Provisions

  • Designates September 2018 as Pulmonary Fibrosis Awareness Month.
  • Expresses Senate support for increased research, education, and community efforts related to pulmonary fibrosis.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateFloor Latest Action

Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Voice Vote. (consideration: CR S6311; text: CR S6308)

September 25, 2018

View full timeline
SenateIntro Referral

Introduced in Senate

September 25, 2018

SenateFloor

Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Voice Vote. (consideration: CR S6311; text: CR S6308)

September 25, 2018

Floor Debate

1 member

What members said about S.Res. 648 on the floor

1 Republican
Mitch McConnell
Sen. Mitch McConnellR-KY · Sep 25, 2018

Mr. President, I ask unanimous consent that the Senate now proceed to the en bloc consideration of the following Senate resolutions, which were submitted earlier today: S. Res. 648, 649, 650, 651,…

Bill Text

Latest available legislative text

Reading Mode
Latest
Agreed to SenateIssued September 25, 2018

III

115th CONGRESS

2d Session

S. RES. 648

IN THE SENATE OF THE UNITED STATES

September 25, 2018

Mr. Coons (for himself, Mr. Crapo, Ms. Klobuchar, Mr. Blumenthal, Mr. Murphy, Ms. Warren, Mr. Hatch, Ms. Smith, Mr. King, and Mr. Risch) submitted the following resolution; which was considered and agreed to

RESOLUTION

Designating September 2018 as Pulmonary Fibrosis Awareness Month.

Whereas pulmonary fibrosis is a debilitating and ultimately fatal lung condition that causes progressive scarring in the lungs and has no definitive cause;

Whereas as many as 200,000 individuals in the United States are known to suffer from pulmonary fibrosis, the majority of whom are aged 50 and older;

Whereas the average life expectancy from the diagnosis of the idiopathic form of pulmonary fibrosis is just 2.8 years, and as many as 80 percent of idiopathic pulmonary fibrosis patients die within 5 years of diagnosis;

Whereas pulmonary fibrosis takes the lives of 40,000 or more individuals in the United States each year—approximately 1 individual every 13 minutes;

Whereas many patients afflicted with pulmonary fibrosis are misdiagnosed for 1 year or longer after the patients are presenting with pulmonary fibrosis symptoms;

Whereas, as of July 2018, there are no confirmed biomarkers for screening and testing for pulmonary fibrosis;

Whereas a cure, treatment, or drug to halt the fibrotic process in pulmonary fibrosis does not yet exist;

Whereas the symptoms of pulmonary fibrosis vary from person to person and include shortness of breath, a dry cough, fatigue, weight loss, and aching muscles and joints;

Whereas volunteers, researchers, caregivers, and medical professionals are working to improve the quality of life for individuals with pulmonary fibrosis and for the families of those individuals; and

Whereas developing more effective treatments for pulmonary fibrosis and providing access to quality care to individuals with pulmonary fibrosis requires increased research, education, and community support services: Now, therefore, be it

That the Senate—

(1)

designates September 2018 as Pulmonary Fibrosis Awareness Month;

(2)

supports the goals and ideals of Pulmonary Fibrosis Awareness Month;

(3)

continues to support more robust and accelerated research to develop more effective treatments for pulmonary fibrosis and to ultimately find a cure for the disease;

(4)

recognizes the courage and contributions of individuals with pulmonary fibrosis who participate in vital clinical trials to advance the knowledge of the disease; and

(5)

commends the dedication of organizations, volunteers, researchers, and millions of individuals in the United States and abroad working to improve the quality of life for individuals with pulmonary fibrosis and the families of those individuals.